Direct‐acting antivirals during or after immunochemotherapy in hepatitis C virus–positive diffuse large B‐cell lymphomas
Michele Merli, Marco Frigeni, Manuel Gotti, Paolo Grossi, Raffaele Bruno, Francesco Passamonti, Luca Arcaini – 5 April 2017
Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice
Kang Ho Kim, Sungwoo Choi, Ying Zhou, Eun Young Kim, Jae Man Lee, Pradip K. Saha, Sayeepriyadarshini Anakk, David D. Moore – 5 April 2017 – The nuclear receptors farnesoid X receptor (FXR; NR1H4) and small heterodimer partner (SHP; NR0B2) play crucial roles in bile acid homeostasis. Global double knockout of FXR and SHP signaling (DKO) causes severe cholestasis and liver injury at early ages. Here, we report an unexpected beneficial impact on glucose and fatty acid metabolism in aged DKO mice, which show suppressed body weight gain and adiposity when maintained on normal chow.
Direct‐acting antivirals during or after immunochemotherapy in hepatitis C virus–positive diffuse large B‐cell lymphomas
Michele Merli, Marco Frigeni, Manuel Gotti, Paolo Grossi, Raffaele Bruno, Francesco Passamonti, Luca Arcaini – 5 April 2017
How to identify patients with advanced liver disease in the community?
Terry Cheuk‐Fung Yip, Vincent Wai‐Sun Wong – 5 April 2017
FABP1 as a novel potential biomarker for predicting mortality in acetaminophen‐induced acute liver failure
Heng Fan, Jian‐hua Zhu – 2 April 2017
Overt acute hepatitis B is more severe in female patients
Ming‐Ling Chang, Yun‐Fan Liaw – 2 April 2017
Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study
Tai‐Shuan Lai, Mei‐Hsuan Lee, Hwai‐I Yang, San‐Lin You, Sheng‐Nan Lu, Li‐Yu Wang, Yong Yuan, Gilbert L'Italien, Kuo‐Liong Chien, Chien‐Jen Chen, for the REVEAL‐HCV Study Group – 2 April 2017 – The association between hepatitis C virus (HCV) infection and end‐stage renal disease (ESRD) remains controversial without considering the role of HCV viral load and genotype. This study aimed to determine whether HCV RNA level and genotype affect the risk of developing ESRD.
REPLY:
Constantine J. Karvellas, Jaime L. Speiser, Mélanie Tremblay, William M. Lee, Christopher F. Rose, For the US Acute Liver Failure Study Group – 2 April 2017
Overt acute hepatitis B is more severe in female patients
Ming‐Ling Chang, Yun‐Fan Liaw – 2 April 2017
Allogeneic bone marrow–derived mesenchymal stromal cells for hepatitis B virus–related acute‐on‐chronic liver failure: A randomized controlled trial
Bing‐liang Lin, Jun‐feng Chen, Wei‐hong Qiu, Ke‐wei Wang, Dong‐ying Xie, Xiao‐yong Chen, Qiu‐li Liu, Liang Peng, Jian‐guo Li, Yong‐yu Mei, Wei‐zhen Weng, Yan‐wen Peng, Hui‐juan Cao, Jun‐qiang Xie, Shi‐bin Xie, Andy Peng Xiang, Zhi‐liang Gao – 1 April 2017 – Mortality from hepatitis B virus (HBV)–related acute‐on‐chronic liver failure (ACLF) is high due to limited treatment options. Preclinical and clinical investigations have proved that treatment with mesenchymal stromal cells (MSCs) is beneficial for recovery from liver injury.